
Monday, July 29, 2024 2:48:41 PM
Plus, Viking didn't publish the results on ClinicalTrials.gov for Phase 1 and Phase 2. That is a huge red flag.
There is a lack of transparency from Viking.
I generally am skeptical of Short Term Investments.
The Viking corporate headquarters is a virtual office - another huge red flag.
IG
The First Casualty of Emotion is Reason.
Recent VKTX News
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/03/2025 07:31:13 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/03/2025 07:30:32 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 07/03/2025 05:05:10 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 07/03/2025 05:01:10 PM
- Viking Therapeutics Announces Initiation of Phase 3 Obesity Clinical Program with GLP-1/GIP Agonist VK2735 • PR Newswire (US) • 06/25/2025 11:03:00 AM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 04/24/2025 08:37:31 PM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 04/23/2025 09:26:31 PM
- Form DEFR14A - Revised definitive proxy soliciting materials • Edgar (US Regulatory) • 04/23/2025 09:25:23 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/23/2025 08:05:59 PM
- Viking Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update • PR Newswire (US) • 04/23/2025 08:05:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/23/2025 08:01:15 PM
- Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend] • Edgar (US Regulatory) • 04/23/2025 02:00:08 PM
- Viking Therapeutics to Report Financial Results for First Quarter 2025 on April 23, 2025 • PR Newswire (US) • 04/16/2025 08:05:00 PM
- Form 4/A - Statement of changes in beneficial ownership of securities: [Amend] • Edgar (US Regulatory) • 04/08/2025 11:05:30 PM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 04/08/2025 09:23:18 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 04/08/2025 09:03:57 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/02/2025 10:29:36 PM
- Viking Therapeutics Announces Completion of Enrollment in Phase 2 VENTURE-Oral Dosing Trial of VK2735 Tablet Formulation in Patients with Obesity • PR Newswire (US) • 03/26/2025 11:05:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/11/2025 11:05:08 AM
- Viking Therapeutics Signs Broad Manufacturing Agreement With CordenPharma to Support Commercialization of VK2735 • PR Newswire (US) • 03/11/2025 11:03:00 AM
- Viking Therapeutics to Participate at Upcoming Investor Conferences • PR Newswire (US) • 03/04/2025 09:05:00 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 02/26/2025 09:32:42 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/05/2025 09:07:52 PM
- Viking Therapeutics Reports Fourth Quarter and Year-End 2024 Financial Results and Provides Corporate Update • PR Newswire (US) • 02/05/2025 09:05:00 PM
Glidelogic Corp. Announces Release of First AI-Generated Novel "The Thirteenth Proposal" • GDLG • Jul 11, 2025 12:20 PM
Fifty1 AI Labs' REVIVE Clinical Trial Redefines Long COVID Treatment, Pioneering AI-Driven Therapies and Propelling Fifty 1 Labs, Inc. Toward $50M Valuation and Global Biotech Leadership • FITY • Jul 10, 2025 8:30 AM
Aspire Biopharma Holdings, Inc., Announces Positive Consumer Feedback from Company Sampling of BUZZ BOMB™, its New Sublingual Pre-Workout Supplement • ASBP • Jul 9, 2025 9:15 AM
Breaking Through: Systemic Genetic Medicines for Hard-to-Treat Cancers • IBRX • Jul 9, 2025 9:00 AM
Fifty 1 Labs, Inc. Announces Bold Expansion Plan Powered by Nobel Prize Laureate Management Team, Cutting-Edge AI Healthcare Innovation and $350K Leadership Investment • FITY • Jul 8, 2025 8:30 AM
Avant Technologies and Partner, Ainnova, Launch Transformative Preventative Care Model for Chronic Patients Across Latin America • AVAI • Jul 8, 2025 8:00 AM